The ESC Protocol That Cut Costs and Shortened Stays. A Critical Correspondence Now Asks Whether Opioid-Exposed Newborns Are Paying the Price.

Author: John Konsin, Principal Founder, Prapela, Inc. | April 21, 2026

We do not withhold opioid medication from adults until suffering renders daily function impossible, to say nothing of waiting until physiological distress impairs basic function. It is unclear why we would be more comfortable with suffering in neonates than we are with suffering in adults.

— McGregor & Graber, Pediatric Research, April 2026

It comes from a correspondence just published in Pediatric Research by Elisabeth McGregor of Nationwide Children’s Hospital and Abraham Graber of The Ohio State University Wexner Medical Center. Its title: Popular protocol or evidence-based practice: a reassessment of “Eat, Sleep, Console.“

It is not a new clinical study. It is something more important: a careful, unflinching examination of whether the evidence driving ESC’s near-universal adoption actually tells us that opioid-exposed newborns are better off.

The Three Wins That Aren’t What They Seem

ESC’s rise has been built on three compelling metrics:

• Reduced opioid use
• Shorter NICU stays (nearly 50% reduction in average length of stay)
• Lower costs (48% reduction in average variable cost per patient)

These numbers are real. But McGregor and Graber ask a question that has gone largely unasked: do any of these measure how these infants are actually doing?

The answer, they argue, is no.

No ESC trial has demonstrated improvements in morbidity or mortality compared to FNASS. Reduced opioid use sounds good, but it hasn’t been validated as a proxy for better outcomes in this population. And the cost savings are almost entirely attributable to shorter stays. They aren’t an independent signal. They’re a mathematical consequence.

The Cold Turkey Problem

Here is the mechanism the field has been reluctant to examine.

Opioid medication, when administered, delays discharge because safe weaning takes time. ESC is designed to minimize opioid use. So when ESC produces a 50% shorter stay, what is actually happening?

McGregor and Graber are direct: it may simply mean that under ESC, neonates more often go cold turkey, or when opioids are received via breastfeeding, are weaned rapidly, rather than undergoing a careful, protocol-guided opioid wean.

A shorter stay driven by less treatment is not evidence of better care.

And with long-term neurodevelopmental follow-up data from the ESC-NOW trial still pending, we don’t yet know what abrupt opioid discontinuation means for these infants at 12, 24, or 36 months.

The Ethical Question Nobody Has Asked Out Loud

This is where McGregor and Graber’s argument cuts deepest.

ESC withholds opioid treatment until three functional thresholds are breached:

• The infant cannot eat more than one ounce per feed,
• Cannot sleep for more than one hour uninterrupted, or
• Cannot be consoled within ten minutes

Think about what that means. We wait for suffering to impair basic function before treating it.

We do not apply this standard to adults. We do not apply it to any other patient population. The authors ask plainly why neonates, among the most vulnerable patients in any hospital, are held to a different standard.

What ESC Actually Got Right, and What It Didn’t Fix

To be fair to ESC, and to be precise about where Prapela stands: ESC did produce one genuine clinical advance.

It got opioid-exposed babies out of the overstimulating NICU environment and into calmer, quieter step-down units. For infants whose developing nervous systems are acutely sensitive to sensory overload, that matters. It is a real benefit.

What ESC did not fix, and what its evidence base cannot currently demonstrate, is whether those infants are suffering less, developing better, and receiving care calibrated to their actual neurobiological needs.

The authors are also clear: they are not defending Finnegan. FNASS was never validated. FNASS-driven NICU admissions may be harmful. The shift away from it is overdue.

What is needed is not just an alternative to FNASS. It is the right alternative.

Where Prapela Fits

At Prapela, we read this correspondence as a precise articulation of the problem our SVS Hospital Bassinet is designed to address.

NOWS is a condition of CNS dysregulation. Opioid withdrawal creates neurological hyperarousal that drives every symptom both ESC and Finnegan are measuring: tremors, excessive crying, disrupted sleep, feeding difficulty, and autonomic instability. Our stochastic vibrotactile stimulation (SVS) technology directly addresses the underlying biology, delivering calibrated, continuous sensory input that engages the somatosensory system, promotes autonomic regulation, and reduces CNS hyperexcitability at the root of withdrawal distress.

It is a non-pharmacological intervention on the biology of suffering, not a protocol change, not a scoring adjustment, and not contingent on which clinical framework a hospital uses.

Under ESC: The SVS Bassinet helps opioid-exposed newborns be consoled more readily. Clinically proven: Prapela SVS is the only FDA-authorized therapy for opioid-exposed newborns. Each hour of SVS delivers a consoling effect statistically equivalent to an hour of caregiver holding, providing continuous, passive soothing that reduces caregiver burden without interrupting care.

Under Finnegan/FNASS: By reducing CNS hyperarousal, the SVS Bassinet addresses the symptom clusters most likely to elevate Finnegan scores and trigger pharmacological intervention thresholds. The pivotal trial supporting the FDA’s authorization of Prapela’s device reported its impact on pharmacological treatment in severe cases of NOWS patients. Due to the small sample size of pharmacologically treated newborns in the study, no specific claims regarding reduced pharmacological treatment are made for the device.

For hospitals in transition: No workflow changes required. The Prapela SVS Bassinet integrates with existing NICU and step-down unit setups, regardless of the assessment framework in use.

The Question Worth Sitting With

McGregor and Graber close their correspondence with this:

“The cost of this rush to consensus will be paid for by the distress of the very newborns ESC aims to help.”

That deserves a serious response, not defensiveness, not a retreat to Finnegan, but a genuine commitment to tools and approaches that address neonatal suffering directly and generate the long-term outcome data the field urgently needs.

We are building that evidence base for the Prapela SVS Bassinet. We welcome partnerships with institutions conducting the rigorous prospective research McGregor and Graber call for.

In the meantime, opioid-exposed newborns are in NICUs and step-down units today. They deserve interventions that address their biology, reduce their distress, and work within whatever clinical framework their care team trusts.

That is what the Prapela SVS Hospital Bassinet is designed to provide.

Source: McGregor, E. & Graber, A. Popular protocol or evidence-based practice: a reassessment of “Eat, Sleep, Console.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-04948-y

Coverage: BioEngineer.org (April 18, 2026). https://bioengineer.org/reevaluating-eat-sleep-console-protocol-effectiveness/

About Prapela Prapela is a medical device company dedicated to improving outcomes for neonates with Neonatal Opioid Withdrawal Syndrome (NOWS). The Prapela SVS Hospital Bassinet uses proprietary stochastic vibrotactile stimulation technology to support CNS regulation in opioid-exposed newborns, and is fully compatible with both ESC and Finnegan-based treatment protocols.

prapela.com | email: info@prapela.com